Clinical Trials Directory

Trials / Completed

CompletedNCT00380900

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Test Article or Placebo Administered Orally to Healthy and Osteoarthritis Subjects.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and tolerbility of ascending multiple oral doses of AGG-523 in healthy subjects and in subjects with osteoarthritis.

Conditions

Interventions

TypeNameDescription
DRUGAGG-523

Timeline

Start date
2006-07-01
Completion
2007-02-01
First posted
2006-09-27
Last updated
2007-12-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00380900. Inclusion in this directory is not an endorsement.